Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 06.07.2026 1 Adv Radiat Oncol 1 Adv Sci (Weinh) 1 Am J Clin Pathol 1 An Sist Sanit Navar 1 Anal Chem 1 Ann Surg Oncol 1 Anticancer Res 1 ANZ J Surg 1 Arch Ital Urol Androl 1 Arch Toxicol 1 Biofactors 1 Biomaterials 3 BJU Int 1 BJUI Compass 1 BMC Biotechnol 1 BMC Cancer 1 BMC Infect Dis 1 BMC Med Imaging 1 BMC Med Res Methodol 1 BMC Surg 6 BMC Urol 1 Cancer 1 Cancer Cytopathol 1 Cancer Genomics Proteomics 1 Cancer Immunol Res 1 Cancer Med 1 Cancer Metastasis Rev 1 Cent European J Urol 1 Clin Cancer Res 2 Clin Genitourin Cancer 1 Clin J Gastroenterol 1 Discov Oncol 1 Drugs Context 1 Environ Int 1 Eur J Surg Oncol 1 Eur Urol 2 Eur Urol Oncol 2 Front Immunol 2 Front Oncol 1 Front Surg 1 Funct Integr Genomics 1 Hum Genomics 2 In Vivo 1 Int Braz J Urol 1 Int Urol Nephrol 1 iScience 1 J Biol Chem 1 J Exp Clin Cancer Res 1 J Magn Reson Imaging 1 J Nippon Med Sch 1 J Proteome Res 2 J Robot Surg 1 J Transl Med 1 J Vis Exp 1 Mater Today Bio 1 Mol Biol Rep 1 Nanomedicine 1 Oncologist 1 Oncology 1 Rev Assoc Med Bras (1992) 3 Sci Rep 1 Stud Health Technol Inform 1 Ther Adv Urol 3 Urol Clin North Am 1 Urol J 1 Urol Res Pract 1 Vet Res Commun 1 World J Surg Oncol 7 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Radiat Oncol

1. NOHMI RL, Marques FC, Brito HC, Leite LM, et al
   Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
   Adv Radiat Oncol. 2026;11:102075.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

2. LAO J, Yuan X, Liang S, Deng K, et al
   Targeted Delivery of Indole-3-Pyruvic Acid Suppresses Macrophage Ferroptosis to Enhance CD8(+) T Cell-Mediated Immunotherapy Response in Bladder Cancer.
   Adv Sci (Weinh). 2026 Jul 2:e76319. doi: 10.1002/advs.76319.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

3. MAHAPATRA S, Humble RM, Cordeiro-Rudnisky F, Hafez KS, et al
   Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.
   Am J Clin Pathol. 2026;165:aqag072.
   PubMed         Abstract available
   
   

   
   An Sist Sanit Navar

4. BIDEGAIN GARBALA E, Arteaga Mazuelas M, Jarne Betran V, Abinzano Guillen ML, et al
   [Subacute meningoencephalitis following intravesical BCG instillation immunotherapy].
   An Sist Sanit Navar. 2026;49:e1145.
   PubMed         Abstract available
   
   

   
   Anal Chem

5. JIANG Y, Xue Y, Chen C, Fang T, et al
   Self-Supervised Denoising Network for Quantitative Stimulated Raman Scattering Microscopy in Cross-Type Samples.
   Anal Chem. 2026;98:18596-18606.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
   ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer.
   Ann Surg Oncol. 2026 Jun 29. doi: 10.1245/s10434-026-20051.
   PubMed        
   
   

   
   Anticancer Res

7. SASAKI Y, Endo Y, Ochiai T, Kin M, et al
   Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemical Carcinogen-induced Bladder Cancer.
   Anticancer Res. 2026;46:3651-3659.
   PubMed         Abstract available
   
   

   
   ANZ J Surg

8. CREFFIER CWG, Chemasle C
   Learning Curve and Surgeon Experience in En Bloc Transurethral Resection of Bladder Tumour: A Retrospective Cohort Study.
   ANZ J Surg. 2026;96:1528-1535.
   PubMed         Abstract available
   
   

   
   Arch Ital Urol Androl

9. NOVIARDI DEPP, Seputra KP, Daryanto B, Dhani FK, et al
   Atypical urothelial cells investigation with automated urinalysis and expert review of microscopic sediment as early parameter for suspected bladder cancer patients.
   Arch Ital Urol Androl. 2026;98:15595.
   PubMed         Abstract available
   
   

   
   Arch Toxicol

10. FAYYAZ S, Sauer UG, Li Q, Guthmann H, et al
    Reassessing the carcinogenic potential of dibutyl hydrogen phosphate: new insight from repeated-dose toxicity studies.
    Arch Toxicol. 2026;100:2111-2134.
    PubMed         Abstract available
    
    

    
    Biofactors

11. CHEN Z, Wang S, Sun Z, Liao H, et al
    An AI-Driven Multi-Omics Framework Identifies CASP8 as a Clinically Actionable Pyroptosis Biomarker in Bladder Cancer.
    Biofactors. 2026;52:e70130.
    PubMed         Abstract available
    
    

    
    Biomaterials

12. ZHANG P, Wu JC, Wang H, You HH, et al
    In-situ cascade assembled peptide-drug conjugate for the treatment of bladder cancer by enhancing membrane-entry and lysosome destabilization.
    Biomaterials. 2026;335:124405.
    PubMed         Abstract available
    
    

    
    BJU Int

13. SOPUTRO NA, Wang L, Daher K, Al-Bayati A, et al
    Intraoperative evaluation of detrusor muscle during transurethral resection of bladder tumour using confocal fluorescent microscopy.
    BJU Int. 2026;138 Suppl 1:S49-S55.
    PubMed         Abstract available
    
    
14. AYDOGDU C, Wang B, McSweeney ST, Diaz G, et al
    Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 2. doi: 10.1111/bju.70376.
    PubMed         Abstract available
    
    
15. GHALI F, Tan WS
    A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 3. doi: 10.1111/bju.70377.
    PubMed        
    
    

    
    BJUI Compass

16. ANING J, Catto JWF, Martin R, Chatterton K, et al
    State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK).
    BJUI Compass. 2026;7:e70236.
    PubMed         Abstract available
    
    

    
    BMC Biotechnol

17. ZHANG J, Su S, Liu M, Luo Y, et al
    Nanoparticles co-loaded with bacillus Calmette-Guerin pure protein derivative and doxorubicin for bladder tumor therapy.
    BMC Biotechnol. 2026;26:39.
    PubMed         Abstract available
    
    

    
    BMC Cancer

18. HAO X, Ye C, Lai W, Xu J, et al
    Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022.
    BMC Cancer. 2026;26:805.
    PubMed         Abstract available
    
    

    
    BMC Infect Dis

19. KOSHIBA T, Hakamata M, Tomita Y, Yamagishi I, et al
    Aortoesophageal fistula caused by Mycobacterium bovis following intravesical Bacillus Calmette-Guerin therapy: a case report and literature review.
    BMC Infect Dis. 2026;26:813.
    PubMed         Abstract available
    
    

    
    BMC Med Imaging

20. HALIS A, Celiker D
    Evaluation of large language models for VI-RADS reports: a comparative analysis of zero-shot and few-shot prompting.
    BMC Med Imaging. 2026;26:265.
    PubMed         Abstract available
    
    

    
    BMC Med Res Methodol

21. GASPARINI A, Crowther MJ, Schaffer JM
    Standardized survival probabilities and contrasts between hierarchical units in multilevel survival models.
    BMC Med Res Methodol. 2026;26:45.
    PubMed         Abstract available
    
    

    
    BMC Surg

22. LIANG P, Chen J, Shen J, Wang Y, et al
    Transurethral thulium laser resection via ureterorenoscope for pediatric low-grade urothelial carcinoma of the bladder: a case report.
    BMC Surg. 2026;26:172.
    PubMed         Abstract available
    
    

    
    BMC Urol

23. OZDEN SB, Kalayci A, Gurses I, Ozdemir F, et al
    Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping.
    BMC Urol. 2026;26:41.
    PubMed         Abstract available
    
    
24. GUO Z, Wang G
    Neoadjuvant immunotherapy combined with HER2-targeted antibody-drug conjugate in bladder urothelial carcinoma: a case report.
    BMC Urol. 2026;26:33.
    PubMed         Abstract available
    
    
25. GUNER E, Sam E, Fakir AE, Guneren MS, et al
    Factors predicting ureteral stenosis after transurethral resection of the ureteral orifice: a two-center, retrospective clinical study.
    BMC Urol. 2025;26:24.
    PubMed         Abstract available
    
    
26. ZHOU Q, Bao G, Liu M, Gong L, et al
    Meta-analysis of the association between CTCs and survival outcomes in urothelial carcinoma.
    BMC Urol. 2026;26:95.
    PubMed         Abstract available
    
    
27. ALHAMDANI Z, Obrecht F, Sethi K, Bolton D, et al
    The modified G8 screening tool to predict post-operative complications and survival after robot-assisted radical cystectomy - a pilot study.
    BMC Urol. 2026;26:104.
    PubMed         Abstract available
    
    
28. AVELINO ALN, Goncalves FD, Ferreira JNM, Vasconcelos GR, et al
    Investigation of androgen receptor expression in urothelial carcinoma of the bladder.
    BMC Urol. 2025;25:308.
    PubMed         Abstract available
    
    

    
    Cancer

29. SUN J, Jin K, Ding Y, Wu Y, et al
    Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.
    Cancer. 2026;132:e70515.
    PubMed         Abstract available
    
    

    
    Cancer Cytopathol

30. SAYEGH Y, McNutt B, Le MK, Liao IC, et al
    Accurate focal-plane selection is crucial for artificial intelligence assessment of three-dimensional urine cytology specimens for bladder cancer screening and surveillance.
    Cancer Cytopathol. 2026;134:e70117.
    PubMed         Abstract available
    
    

    
    Cancer Genomics Proteomics

31. ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
    Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades.
    Cancer Genomics Proteomics. 2026;23:777-805.
    PubMed         Abstract available
    
    

    
    Cancer Immunol Res

32. HUNT KS, Cooke S, Kuehm LM, Lobb TA, et al
    Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.
    Cancer Immunol Res. 2026;14:1068-1079.
    PubMed         Abstract available
    
    

    
    Cancer Med

33. ODAGIRI K, Tasaki Y, Naiki T, Morikawa T, et al
    Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.
    Cancer Med. 2026;15:e72072.
    PubMed         Abstract available
    
    

    
    Cancer Metastasis Rev

34. XIE P, Wang Y, Lu L, Chen J, et al
    HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.
    Cancer Metastasis Rev. 2026;45:44.
    PubMed         Abstract available
    
    

    
    Cent European J Urol

35. OZCAN L, Boylu A, Polat EC, Culha MG, et al
    Is the albumin/globulin ratio a predictor of response to neoadjuvant chemotherapy before cystectomy for muscle-invasive bladder cancer?
    Cent European J Urol. 2026;79:103-110.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

36. LOTAN Y, Luu M, Liu M, Tikhonekov S, et al
    Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.
    Clin Cancer Res. 2026 Jul 2. doi: 10.1158/1078-0432.CCR-26-1407.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

37. PICCOLINI A, Paciotti M, Korn SM, Qian Z, et al
    Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).
    Clin Genitourin Cancer. 2026 Jun 5:102595. doi: 10.1016/j.clgc.2026.102595.
    PubMed         Abstract available
    
    
38. RODRIGUEZ-PARRAS P, Angel Arrabal-Polo M, Arrabal-Martin M
    Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review.
    Clin Genitourin Cancer. 2026;24:102596.
    PubMed         Abstract available
    
    

    
    Clin J Gastroenterol

39. WATANABE R, Koshitani T, Hashidume S, Kasho K, et al
    Urinary bladder invasion secondary to dissemination of gallbladder cancer: an unusual presentation.
    Clin J Gastroenterol. 2026;19:684-689.
    PubMed         Abstract available
    
    

    
    Discov Oncol

40. LIU H, Chu Y, Hou J, Wang Y, et al
    Targeting macrophage-associated core genes for prognostic prediction and therapeutic insights in bladder cancer.
    Discov Oncol. 2026 Jun 27. doi: 10.1007/s12672-026-05338.
    PubMed         Abstract available
    
    

    
    Drugs Context

41. JANG A, Grier AL, Sheng IY, Bari S, et al
    Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer.
    Drugs Context. 2026;15:2025-9-1.
    PubMed         Abstract available
    
    

    
    Environ Int

42. ERICHSEN DW, Kyro C, Schullehner J, Rosthoj S, et al
    Source-specific nitrate and nitrite intake and bladder cancer: findings from the Danish Diet, Cancer and Health Cohort.
    Environ Int. 2026;214:110387.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

43. KOHLI M, Goel S, Iqbal A, Aggarwal A, et al
    Impact of 18-FDG PET-CT on the preoperative staging and management of Incidental Gall Bladder Cancer (IGBC)- A prospective study from a tertiary care centre in North India.
    Eur J Surg Oncol. 2026;52:111982.
    PubMed         Abstract available
    
    

    
    Eur Urol

44. CONTIERI R, van der Heijden AG, Mertens LS
    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.
    Eur Urol. 2026 Jul 2:S0302-2838(26)02181-0. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Oncol

45. CHANG Y
    Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol O
    Eur Urol Oncol. 2026 Jun 28:S2588-9311(26)00169.
    PubMed        
    
    
46. CONTIERI R, Hurle R
    Reply to Yue Chang's Letter to the Editor re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective H
    Eur Urol Oncol. 2026 Jun 29:S2588-9311(26)00181.
    PubMed        
    
    

    
    Front Immunol

47. GAMBINA K, Tymm C, Paiola M, Tanji K, et al
    Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma.
    Front Immunol. 2026;17:1793351.
    PubMed         Abstract available
    
    
48. QIU H, Du H, Li X, Wang X, et al
    Urinary tract infection caused by rare yeast Vanrija humicola in a urothelial carcinoma patient: a case report and literature review.
    Front Immunol. 2026;17:1845780.
    PubMed         Abstract available
    
    

    
    Front Oncol

49. MOMENAH MA, Al-Qahtani WS
    An exploratory study of BLCA-4 expression, STR analysis, and urothelial cytology in smokers versus non-smokers with bladder cancer.
    Front Oncol. 2026;16:1851761.
    PubMed         Abstract available
    
    
50. ZHAO Z, Liu X, Zhong Q, Liu L, et al
    Choosing neoadjuvant therapy for muscle-invasive bladder cancer based on efficacy-safety trade-off: a network meta-analysis.
    Front Oncol. 2026;16:1819312.
    PubMed         Abstract available
    
    

    
    Front Surg

51. LEITSMANN C, Reese AS, Zigeuner R, Zurl H, et al
    Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?
    Front Surg. 2026;13:1813017.
    PubMed         Abstract available
    
    

    
    Funct Integr Genomics

52. XIN S, Li G, Zhao L, Su J, et al
    The BCAA metabolism-related gene BCAT1 promotes the progression of bladder urothelial carcinoma through the PI3K/AKT/mTOR signalling pathway.
    Funct Integr Genomics. 2026;26:39.
    PubMed         Abstract available
    
    

    
    Hum Genomics

53. RAN M, Chen X, Xiao G, Huang R, et al
    Exploration of neutrophil-associated genes in the prognosis of bladder urothelial carcinoma based on a machine learning and multi-omics data integration framework.
    Hum Genomics. 2026;20:37.
    PubMed         Abstract available
    
    

    
    In Vivo

54. SHIRAISHI Y, Furubayashi N, Tsujita J, Takayama A, et al
    Ureteral Orifice Stricture After Transurethral Resection of Bladder Tumors Involving the Ureteral Orifice or Adjacent Area: Clinical Course and Outcomes.
    In Vivo. 2026;40:2327-2334.
    PubMed         Abstract available
    
    
55. KUO YC, Wang HY, Liao TL, Weng YS, et al
    A miR-124-3p/PKC-delta Regulatory Axis Restrains Bladder Cancer Growth and Malignant Progression.
    In Vivo. 2026;40:1992-2002.
    PubMed         Abstract available
    
    

    
    Int Braz J Urol

56. CHEN N, Chen L, Cai J, Tan M, et al
    Extraperitoneal Single-Port Robotic-Assisted Radical Cystectomy with Orthotopic Ne-obladder: Technique and Surgical Considerations.
    Int Braz J Urol. 2027;53:e20260422.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

57. WANG Y, Zhao T, Liang B, Zhen L, et al
    Multiparametric MRI-derived radiomic signatures enable noninvasive prediction of HER2 expression in bladder cancer.
    Int Urol Nephrol. 2026 Jul 3. doi: 10.1007/s11255-026-05256.
    PubMed         Abstract available
    
    

    
    iScience

58. XIAO X, Jia X, Shen R, Song D, et al
    Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer.
    iScience. 2026;29:116353.
    PubMed         Abstract available
    
    

    
    J Biol Chem

59. PILALA KM, Papadimitriou AM, Papadimitriou MA, Panoutsopoulou K, et al
    Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression.
    J Biol Chem. 2026 Jun 29:113302. doi: 10.1016/j.jbc.2026.113302.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

60. SUN RM, Yang Y, Lai YD, Wang HN, et al
    BCG-trained macrophages promote pan-anti-tumor activity through epigenetic rewiring of NOX2-ROS axis.
    J Exp Clin Cancer Res. 2026;45:134.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

61. GUO E, Chen L, Li Y, Fan P, et al
    A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels.
    J Magn Reson Imaging. 2026 Jul 2. doi: 10.1002/jmri.70401.
    PubMed         Abstract available
    
    

    
    J Nippon Med Sch

62. IMURA S, Ogi Y, Ishimaru K, Koga S, et al
    Small Intestinal Adhesion at a Parastomal Hernia of the Ileal Conduit and Hernia Repair with Laparoscopy and Tailored Mesh: A Case Report.
    J Nippon Med Sch. 2026;93:279-283.
    PubMed         Abstract available
    
    

    
    J Proteome Res

63. MOUSA MK, Carvalho LB, Giddey AD, Figueiredo A, et al
    Evaluation of FASP for Mass Spectrometry-Based Untargeted Metabolomics Analysis of Urine Samples.
    J Proteome Res. 2026;25:3769-3777.
    PubMed         Abstract available
    
    

    
    J Robot Surg

64. PU C, Lv Z, Chen G
    A systematic review and meta-analysis: evaluating the enhanced recovery after surgery protocol for perioperative care in robot-assisted radical cystectomy.
    J Robot Surg. 2026;20:449.
    PubMed         Abstract available
    
    
65. LI Z, Yan R, Zhao K, Xiao X, et al
    Global trends in robot-assisted radical cystectomy: a bibliometric and visualization analysis.
    J Robot Surg. 2026;20:245.
    PubMed         Abstract available
    
    

    
    J Transl Med

66. FANG C, Dai J, Weng Z, Zhang L, et al
    A machine learning-based epigenetic signature reveals YTHDC1 stabilizes POU5F1 to oppose tumor progression.
    J Transl Med. 2026;24:608.
    PubMed         Abstract available
    
    

    
    J Vis Exp

67. ZHANG J, Wu B, Xie C, Qian X, et al
    Treatment-Related Cystitis During Intravesical Chemotherapy: Incidence, Risk Factors, And Nursing-Pathway Associations.
    J Vis Exp. 2026;.
    PubMed         Abstract available
    
    

    
    Mater Today Bio

68. ZHANG X, Xin P, Du Y, Wang R, et al
    Biomimetic delivery of a STING agonist via tumor antigen-primed dendritic cell membrane nanovesicles for bladder cancer immunotherapy.
    Mater Today Bio. 2026;39:103333.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

69. ATIA N, Osman Y, Abdel-Aziz AF, Refaat S, et al
    Angiotensin Converting Enzyme (ACE) insertion/deletion (rs1799752) gene polymorphism and bladder cancer aggressiveness in Egyptian patients: A pilot case-control study.
    Mol Biol Rep. 2026;53:1058.
    PubMed         Abstract available
    
    

    
    Nanomedicine

70. AL-ASFORY K, Mortada WI, El-Khawaga OY, Magar RW, et al
    Mentha-derived green synthesized ZnO nanoparticles potentiate methotrexate induced molecular and migratory inhibition via gene expression modulation in T24 bladder cancer cells.
    Nanomedicine. 2026 Jul 3:102991. doi: 10.1016/j.nano.2026.102991.
    PubMed         Abstract available
    
    

    
    Oncologist

71. MAHMUD S, Dwyer Orr L, Cline M, Mirsalehi A, et al
    Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.
    Oncologist. 2026 Jun 27:oyag243. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Oncology

72. LIU J, Allen RC, Stephens JT Jr, Huang H, et al
    Selective Tumor Cytotoxicity via Singlet Oxygen: Investigating Eosinophil Peroxidase and Myeloperoxidase in Cancer Therapy.
    Oncology. 2026;104:849-862.
    PubMed         Abstract available
    
    

    
    Rev Assoc Med Bras (1992)

73. BULUT AS, Kizilkan Y
    Evaluation and comparison of voided urine and bladder washing cytologies according to the Paris system.
    Rev Assoc Med Bras (1992). 2026;72:e20251936.
    PubMed         Abstract available
    
    

    
    Sci Rep

74. ZHANG G, Hou J, Guo M, JiamingYan, et al
    Integrating whole-genome bisulfite sequencing and TCGA data reveals methylation patterns associated with the MTHFR 677 C > T Variant.
    Sci Rep. 2026;16:19756.
    PubMed         Abstract available
    
    
75. SANO T, Ikeda J, Yoshida T, Nakamoto T, et al
    Hydronephrosis modifies the association between ureteroscopy and intravesical recurrence risk after radical nephroureterectomy for upper tract urothelial carcinoma.
    Sci Rep. 2026;16:18820.
    PubMed         Abstract available
    
    
76. HEKMATIRAD S, Gholizadeh F, Montazeri S, Sharifi L, et al
    Patient-derived organoids as a predictive platform for drug sensitivity in bladder cancer.
    Sci Rep. 2026 Jun 27. doi: 10.1038/s41598-026-59564.
    PubMed         Abstract available
    
    

    
    Stud Health Technol Inform

77. YE Z, Cui W, Theodorescu D, Finkelstein J, et al
    Estimating Mosaic Loss of the Y Chromosome in Male Bladder Cancer Participants Using "All of Us" Data.
    Stud Health Technol Inform. 2026;338:443-447.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

78. GHOREIFI A, Dudinec JV, Refugia JM, Zahir M, et al
    Complete pathological response in patients with bladder cancer: predictors and outcomes.
    Ther Adv Urol. 2026;18:17562872261458110.
    PubMed         Abstract available
    
    

    
    Urol Clin North Am

79. FILON M, Kabra S, Smelser W, Schmidt B, et al
    Transurethral Resection of Bladder Tumors: Evolving Standards of Care-Optimizing Resection, Staging Accuracy, and Recurrence Reduction.
    Urol Clin North Am. 2026;53:365-376.
    PubMed         Abstract available
    
    
80. TAZEGUL TE, O'Donnell M, Hougen HY
    Bacillus Calmette-Guerin Therapy: Optimizing Outcomes amid Challenges.
    Urol Clin North Am. 2026;53:413-427.
    PubMed         Abstract available
    
    
81. STECKENRIDER H, Delgado J, Ritch C
    Surveillance Protocols: Balancing Patient Burden and Cancer Control.
    Urol Clin North Am. 2026;53:453-461.
    PubMed         Abstract available
    
    

    
    Urol J

82. AKARKEN I, Tarhan H, Karaoz F, Deliktas H, et al
    Clinical Features and Treatment Outcomes of Large Bladder Tumors Nearly Filling the Bladder.
    Urol J. 2026;23:48-53.
    PubMed         Abstract available
    
    

    
    Urol Res Pract

83. Z KHAN M, Atta MA, Kotb A, Ismail A, et al
    Beyond the Rotisserie: Dispelling the Myths of Intravesical Therapy and Pioneering a Precision Future for Bladder Cancer.
    Urol Res Pract. 2026;52:1-8.
    PubMed         Abstract available
    
    

    
    Vet Res Commun

84. KITNITCHEE M, Sirivisoot S, Siripoonsub J, Chimnakboon N, et al
    BRAF(V595E) detection, uroplakin II expression and PAS staining for diagnosing canine urothelial carcinoma.
    Vet Res Commun. 2026;50:245.
    PubMed         Abstract available
    
    

    
    World J Surg Oncol

85. LU X, You X, Liu T, Wei Y, et al
    The gene mutation pattern of urachal squamous cell carcinoma resembles that of gastrointestinal tumors: a rare case with favorable prognosis following surgery and adjuvant chemotherapy.
    World J Surg Oncol. 2026;24:224.
    PubMed         Abstract available
    
    

    
    World J Urol

86. RAM P, Merseburger AS, Huabkong M, Tohi Y, et al
    Unresolved questions in the sequencing of systemic therapy for advanced urothelial carcinoma.
    World J Urol. 2026;44:307.
    PubMed         Abstract available
    
    
87. MANGOLD MH, Wieland VLS, Grilli M, Studier-Fischer A, et al
    Tranexamic acid in radical cystectomy: a systematic review and meta-analysis of efficacy and safety.
    World J Urol. 2025;43:560.
    PubMed         Abstract available
    
    
88. YUAN S, Yang K, Wu H, Peng L, et al
    Diagnostic performance of artificial intelligence in detecting bladder carcinoma.
    World J Urol. 2025;44:63.
    PubMed         Abstract available
    
    
89. KACAN T, Tezcan B, Yildiz AK, Gokkurt Y, et al
    Impact of spinal versus general anesthesia on dwell time of early immediate intravesical epirubicin administration following transurethral resection of bladder tumor: an observational study.
    World J Urol. 2026;44:325.
    PubMed         Abstract available
    
    
90. MASTROIANNI R, Ragusa A, Iannuzzi A, Tuderti G, et al
    Impact of transvaginal extraction on continence after robotic cystectomy with orthotopic neobladder.
    World J Urol. 2026;44:197.
    PubMed         Abstract available
    
    
91. LIU Y, Song Y, Qi N, Han C, et al
    Immediate Vs. Delayed single post-operative intravesical instillation of chemotherapy in reducing bladder recurrence rate in upper tract urothelial carcinoma patients after radical nephroureterectomy.
    World J Urol. 2026;44:226.
    PubMed         Abstract available
    
    
92. CRETTENAND F, Papagiannakis A, Stritt K, Grillo N, et al
    Impact of continuous local anesthetic wound infiltration on postoperative outcomes following open radical cystectomy: a comprehensive evaluation.
    World J Urol. 2026;44:315.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum